Novartis announced today the appointment of Dr Klaus Moosmayer as Chief Ethics, Risk and Compliance Officer. He will report to Vas Narasimhan, M.D., CEO of Novartis and become a member of the Executive Committee of Novartis (ECN). Dr. Moosmayer will join Novartis on December 1, 2018 and will be based in Basel, Switzerland. He succeeds Shannon Thyme Klinger who was recently appointed Group General Counsel.
Novo Nordisk joins Evotec as drug discovery partner
Latest NewsNovo Nordisk and Evotec have joined forces to find new drugs in the lucrative diabetes and obesity markets.
Greg Rush joins Parexel as Executive VP & CFO
AppointmentsParexel International Corporation today announced the appointment of Greg Rush as Executive Vice President and Chief Financial Officer.
Genkyotex cashes in €7.5m
Latest NewsFrench Genkyotex SA has secured an €7.5m gross financing to expand the scope of its Phase II product GKT831 in Primary Biliary Cholangitis (PBC).
Roche’s Alecensa approved in China
Latest NewsRoche AGs ALK blocker Alecensa (alectinib) has been granted market approval by China National Drug Administration as first line NSCLC monotherapy in patients with ALK-positive non small cell lung cancer (NSCLC)
Pfizer partners with Biontech in US$425m deal
Latest NewsBioNTech AG has partnered with Pfizer to develop a mRNA-based flu vaccine.
New lupus target unraveled
Latest NewsEGFR agonists support the protective effect of Langerhans against UV-induced damage of skin cells, a hallmark of lupus erythematosus and other autoimmune and dermatologic conditions, a team of US and German researchers report.
Zelluna appoints Dr. Namir Hassan
AppointmentsZelluna Immunotherapy, a biotechnology company specializing in T-cell receptor (TCR) immunotherapies, has announced the appointment of Dr. Namir Hassan as chief scientific officer (CSO).
Small molecule restores liver regeneration
Latest NewsA team of Scots, Belgian and Spanish researchers claim they have found a target to prevent failure of liver regeneration following intoxination or acute injury.
Novartis names Klaus Moosmayer as Chief Ethics Risk and Compliance Officer
AppointmentsNovartis announced today the appointment of Dr Klaus Moosmayer as Chief Ethics, Risk and Compliance Officer. He will report to Vas Narasimhan, M.D., CEO of Novartis and become a member of the Executive Committee of Novartis (ECN). Dr. Moosmayer will join Novartis on December 1, 2018 and will be based in Basel, Switzerland. He succeeds Shannon Thyme Klinger who was recently appointed Group General Counsel.
Orchard Therapeutics raise US-$150m
Latest NewsLondon-headquartered gene therapy Orchard Therapeutics has closed a US-$150m series C financing round to push MAAs and BLAs of three late-stage gene therapies by 2021.